Summit Exercises and Training LLC (SummitET®), a Preparedness Solutions Company®, announces the addition of William “Jeff” Skinner, M.D. as the company’s new Subject Matter Expert in Radiology Oncology and Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE). A retired United States Air Force Colonel and former combat flight surgeon, Dr. Skinner will provide clinically-oriented CBRNE support to existing contracts within SummitET’s client portfolio, as well as continuing his translational research and real-world modeling efforts to improve the response to and preparedness for radiological/nuclear events.
“We must continue to study the impact of radiation mitigation and prophylaxis on the hematopoietic, gastrointestinal, immune system as well as delayed health effects from radiation exposure and contamination. I’m interested in improving data integration, decision-making, and risk assessment/management to improve outcomes and drive outcome-oriented research efforts,” said Dr. Skinner.
Dr. Skinner is a graduate of the U.S. Air Force Academy, attended the University of Virginia for medical school and completed a residency in radiation oncology at Montefiore Medical Center/Albert Einstein College of Medicine in New York City. He has served as a combat flight surgeon in Iraq and retired from Walter Reed National Military Medical Center where he was the Program Director for the Radiation Oncology Residency Program, Chief of Military Medical Operations at the Armed Forces Radiobiology Research Institute, and was a Principal Investigator on numerous clinical and translational research projects. Awarded the Defense Distinguished Service Medal for his leadership in nuclear survivability and medical treatment, Dr. Skinner has led advanced modeling efforts involving radiation, blast, and thermal effects and has investigated the impact of biocomplexity and logistics on optimal management of causalities.
“Dr. Skinner is an innovative, operationally and clinically-oriented leader with extensive experience and knowledge in the radiation oncology field. With his unique background and commitment to ongoing translational research and modeling, he is a valuable and exciting asset to our team of experts,” stated John Duda, CEO of SummitET.
